Pediatric Sepsis Endotypes: Recognition and Management
Pediatric sepsis has two distinct transcriptomic endotypes—Endotype A (hyperinflammatory) and Endotype B (hypoinflammatory)—that differ fundamentally in their immune response patterns and mortality risk, though current clinical guidelines do not yet mandate endotype-specific treatment protocols. 1
Understanding Pediatric Sepsis Endotypes
The concept of sepsis endotypes represents a paradigm shift from viewing sepsis as a single syndrome to recognizing distinct biological subgroups with different underlying pathophysiology:
Endotype A (Hyperinflammatory)
- Characterized by excessive immune activation and inflammatory response
- Associated with higher mortality risk when combined with certain clinical features
- May benefit from tight glycemic control strategies (mortality benefit demonstrated in secondary analysis of HALF-PINT and IIT-SBPP trials) 1
- Shows distinct transcriptional profiles that differ from adult sepsis patterns 1
Endotype B (Hypoinflammatory)
- Characterized by immune suppression or dampened inflammatory response
- Different mortality patterns compared to Endotype A
- Does not show mortality benefit from tight glycemic control 1
- Represents the majority of pediatric sepsis cases (approximately 70% in adult studies using pediatric classification) 2
Critical Age-Related Considerations
A major caveat: pediatric and adult sepsis subphenotypes do not perfectly overlap 1. The developmental immune system in children undergoes marked changes from birth through adolescence, fundamentally altering disease susceptibility and outcomes 1. When pediatric endotypes A and B were applied to adult cohorts, they failed to identify consistent mortality differences—in stark contrast to findings in children 1. This underscores that endotype-based management strategies cannot be extrapolated between age groups.
Current Clinical Management Framework
Despite emerging endotype data, the 2020 and 2026 Surviving Sepsis Campaign guidelines do not incorporate endotype-specific treatment algorithms 3, 4. Instead, management remains standardized:
Immediate Recognition and Antimicrobial Therapy
- Septic shock: Start antimicrobials within 1 hour of recognition (strong recommendation) 3
- Sepsis-associated organ dysfunction without shock: Start antimicrobials within 3 hours (weak recommendation) 3
- Obtain blood cultures before antimicrobials if this doesn't cause substantial delay 3
- Use empiric broad-spectrum therapy covering all likely pathogens 3
Fluid Resuscitation
- Administer up to 40-60 mL/kg in boluses (10-20 mL/kg per bolus) over the first hour 3
- Titrate to clinical markers of cardiac output
- Discontinue if signs of fluid overload develop 3
De-escalation Strategy
- Daily assessment for antimicrobial de-escalation 3
- Narrow therapy once pathogen and sensitivities identified 3
- Review empiric therapy indication after 48 hours 3
The Path Forward: Precision Medicine in Pediatric Sepsis
The field is moving toward real-time subphenotyping that could influence clinical decision-making 1. Several current studies are testing feasibility of real-time endotype identification 1. However, most published subphenotyping work remains limited to cohort studies and retrospective analyses 1. Prospective validation studies are needed before clinical implementation.
Potential Future Applications
- Predictive enrichment: Selecting patients with specific biological features for targeted therapies 1
- Metabolic therapy targeting: Hyperinflammatory endotypes may benefit from tight glycemic control 1
- Novel trial designs: Adapting strategies from oncology to test endotype-specific interventions 1
Common Pitfalls to Avoid
- Do not delay standard sepsis management while attempting to determine endotype—current guidelines do not support this approach
- Do not assume adult sepsis endotype data applies to children—the biology is fundamentally different 1
- Do not withhold broad-spectrum antibiotics based on suspected endotype—antimicrobial therapy timing remains paramount 3
- Recognize that endotype determination currently requires transcriptomic analysis—not readily available at bedside 1, 5
Clinical Bottom Line
While pediatric sepsis endotypes A and B represent important biological distinctions with implications for prognosis and potentially for targeted therapies, current evidence-based management follows standardized protocols regardless of endotype 3, 4. The priority remains rapid recognition, prompt antimicrobial administration, appropriate fluid resuscitation, and source control. Endotype-specific interventions remain investigational, with tight glycemic control showing promise specifically for hyperinflammatory phenotypes 1. Until prospective validation studies demonstrate clinical utility of real-time endotyping, standard sepsis management protocols should guide all clinical decisions.